Friday, December 30, 2011

Pertuzumab improved PFS when given with trastuzumab, chemotherapy

SAN ANTONIO — According to data presented, patients with HER-2–positive metastatic or locally recurrent breast cancer had a longer PFS when they received a triple-drug combination that included pertuzumab, trastuzumab and docetaxel vs. patients who only received trastuzumab and docetaxel.

No comments:

Post a Comment